-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17

Benzinga·04/01/2026 12:55:34
Listen to the news
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.